Homebiotech stocks

biotech stocks

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

December 1, 2025

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

December 1, 2025

Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

November 13, 2025

Cardiol Therapeutics’ Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

Cardiol Therapeutics’ Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

November 5, 2025

BioNxt Reports “Intention to Grant” Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies

BioNxt Reports “Intention to Grant” Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies

November 4, 2025

BioNxt Reports “Readiness to Grant” Patent Notification from the Eurasian Patent Organization

BioNxt Reports “Readiness to Grant” Patent Notification from the Eurasian Patent Organization

October 30, 2025

BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug

BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug

October 22, 2025

Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

October 21, 2025

Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027

Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027

October 17, 2025

Wisp & Vesalius Forge Women-Centric Longevity Path With Peptide Therapy Launch

Wisp & Vesalius Forge Women-Centric Longevity Path With Peptide Therapy Launch

October 17, 2025

1 2 3 »